NCT03105375已完成1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 39
- 试验地点
- 2
- 主要终点
- Occurrence and frequency of AEs, changes in laboratory parameters, vital signs and physical examination after single and multiple doses of X842. Summary statistics will be applied.
研究概览
简要总结
The purpose of this study is to assess and analyze the safety, tolerability and PK/PD data following single ascending and multiple ascending doses of X842 in healthy subjects.
详细描述
This is a single-centre, open label, first-in-human study with the primary objective to evaluate safety and tolerability of X842 after administration of single and multiple oral ascending doses to healthy male and female subjects. The study comprises a Single Ascending Dose (SAD) part and a Multiple Ascending Dose (MAD) part including an open-label multiple dose cohort administered active comparator (omeprazole). Four subjects will be included in each of the SAD and MAD cohorts.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Willing and able to give written informed consent for participation in the study.
- •Body Mass Index (BMI) ≥ 18 and ≤ 30 kg/m2 and weight at least 50 kg and no more than 100 kg at screening.
- •Clinically normal medical history, physical findings, vital signs, ECG and laboratory values at the time of screening, as judged by the Investigator.
- •Male subjects must be willing to use condom and if they have a fertile partner, she must use contraceptive methods with a failure rate of < 1% to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the date of dosing until three months after dosing of the IMP.
- •Female subjects must be of non-childbearing potential (defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or post-menopausal females defined as 12 months of amenorrhoea [in questionable cases a blood sample with simultaneous follicle stimulation hormone 25-140 IE/L and estradiol <200 pmol/L is confirmatory]).
排除标准
- •History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
- •Present clinically significant psychiatric diagnosis, at discretion of the Investigator.
- •Any clinically significant illness, medical/surgical procedure or trauma within four weeks of the first administration of investigational medical product.
- •History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past five years, regardless of whether there is evidence of local recurrence or metastases.
- •History of any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs. The investigator is to be guided by evidence of any of the following: history of major gastrointestinal surgery such as gastrectomy, gastroenterostomy, bowel resection or Transjugular Intrahepatic Portosystemic Shunt (TIPS).
- •History or presence of diagnosed and long-term treatment for GERD.
- •Likelihood of having a gastric pH>2 due to for example known autoimmune gastritis or known Helicobacter pylori gastritis.
- •Known severe atrophic gastritis.
- •Vitamin B-12 deficiency and/or chronic Vitamin B-12 substitution.
- •Known malabsorption.
- •Any planned major surgery within the duration of the study.
- •Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody and Human Immunodeficiency Virus (HIV).
- •After 10 minutes of supine rest at the time of screening, any vital signs values outside the following ranges:
- •Systolic BP 90 - 140 mm Hg
- •Diastolic BP 50 - 90 mm Hg
- •Heart rate (HR) 45-90 beats per minute
- •Prolonged QTcF (>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the Investigator.
- •History of severe allergy/hypersensitivity or on-going allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to X842 or omeprazole.
- •Regular use of any prescribed or non-prescribed medication including antacids, analgesics, herbal remedies, vitamins and minerals within two weeks prior to the (first) administration of IMP, except occasional intake of paracetamol (maximum 2 000 mg/day; and not exceeding 6 000 mg/week), at the discretion of the Investigator and nasal decongestants without cortisone or antihistamine for a maximum of 10 days, at the discretion of the Investigator.
- •Administration of another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment with less than three months between administration of last dose and first dose of IMP in this study. Subjects consented and screened but not dosed in previous phase I studies are not excluded.
- •Current smokers or users of nicotine products. Irregular use of nicotine (e.g. smoking, snuffing, chewing tobacco) less than three times per week is allowed before screening visit.
- •Positive screen for drugs of abuse or alcohol at screening or on admission to the unit prior to administration of the IMP.
- •Current or history of alcohol abuse and/or use of anabolic steroids or drugs of abuse.
- •Intake of xanthine and/or taurine containing energy drinks within two days prior to first day of IMP administration.
- •Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to screening.
- •Other protocol-defined inclusion/exclusion criteria may apply
研究组 & 干预措施
Single ascending dose of X842
Experimental
Single ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
干预措施: Single ascending dose of X842 (Drug)
Multiple ascending dose of X842
Experimental
Multiple ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
干预措施: Multiple ascending dose of X842 (Drug)
Losec
Active Comparator
Standard oral dose of omeprazole administered to subjects in one cohort.
干预措施: Losec (Drug)
结局指标
主要结局
Occurrence and frequency of AEs, changes in laboratory parameters, vital signs and physical examination after single and multiple doses of X842. Summary statistics will be applied.
时间窗: Five weeks
Safety and tolerability will be assessed by occurrence and frequency of AEs, changes in laboratory parameters, vital signs and physical examination. The adverse event assessment will follow the recommendations and grading system of Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Summary statistics will be applied.
次要结局
- Measurement of the PK profile (Cmax)(Up to 48 hours after dosing)
- Measurement of the PK profile (t1/2)(Up to 48 hours after dosing)
- Measurement of the PD profile (intragastric pH)(Up to 24 hours after dosing)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT04921878CSPC ZhongQi Pharmaceutical Technology Co., Ltd.29
已完成
1 期
A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy AdultsHealthyNCT01050127Abbott36
已完成
1 期
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly SubjectsHealthyNCT00968422Abbott28
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male SubjectsHealthyNCT02173665Boehringer Ingelheim64
撤回
1 期
A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent SubjectsOpioid Withdrawal (Disorder)Opioid Use DisorderNCT06711640USWM, LLC (dba US WorldMeds)16